RPAM
SION

Rhenman & Partners Asset Management’s Sionna Therapeutics SION Stock Holding History

Rhenman & Partners Asset Management’s Portfolio SION Stock Details SION Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.27M Buy
97,100
+9,600
+11% +$384K 0.4% 79
2026
Q1 		$3.51M Buy
+87,500
New +$3.34M 0.43% 68

Other funds holding SION

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Rhenman & Partners Asset Management's SION Position: Q2 2026 in Review

Rhenman & Partners Asset Management increased its Sionna Therapeutics (SION) stake by 11% in Q2 2026, buying an estimated $384K and bringing the position to 97,100 shares worth $4.27M. The position accounts for 0.4% of the portfolio, ranked #79.

Rhenman & Partners Asset Management first reported a position in SION in Q1 2026 and has held it in 2 quarters since. 146 funds tracked by Wall St. Rank hold SION as of Q2 2026.

  • Rhenman & Partners Asset Management held 97,100 shares of Sionna Therapeutics worth $4.27M as of Q2 2026.
  • Rhenman & Partners Asset Management bought 9,600 Sionna Therapeutics shares in Q2 2026, an estimated $384K.
  • Sionna Therapeutics made up 0.4% of Rhenman & Partners Asset Management's portfolio in Q2 2026, its #79 holding.
  • Rhenman & Partners Asset Management first reported a position in Sionna Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 146 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q2 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.